Life Sciences Research Office (LSRO) Evaluating Adverse Event Reporting Systems for Dietary Supplements January 30-31, 2003 “Open Portion of Meeting”

Slides:

Advertisements

Similar presentations

Tips to a Successful Monitoring Visit

Advertisements

THE JOINT COMMISSION PATIENT BLOOD MANAGEMENT PERFORMANCE MEASURES

1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.

© 2005 Notification and Reporting on Food Incidents: Irish Approach Food & Drugs Authority Bangkok Thailand Dorothy Guina-Dornan.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Department of Patient RelationsMeasuring to Achieve Patient Safety General Information Session.

Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.

1 Critical Incident Reporting Western Highlands Network June 2007.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.

Business and Society: Ethics and Stakeholder Management, 5E Carroll & Buchholtz Copyright ©2003 by South-Western, a division of Thomson Learning. All.

CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’

Standard 5: Patient Identification and Procedure Matching Nicola Dunbar, Accrediting Agencies Surveyor Workshop, 10 July 2012.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

Patient Safety Initiatives Kelly Cronin Director, Patient Safety and Outcomes Research Office of Policy and Planning Office of the Commissioner FDA.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Ken Falci, Ph.D.,Director, OSAS Center for Food Safety and Applied Nutrition (CFSAN) FDA, College Park, MD.

Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

PROPRIETARY NAME EVALUATION AT FDA Jerry Phillips, RPh Associate Director for Medication Error Prevention Office of Drug Safety December 4, 2003.

1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research.

PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?

Industry Recommendations on Evaluating OTC Consumer Behavior Douglas Ws. Bierer, Ph.D. Consumer Healthcare Products Association.

Active Surveillance for Adverse Drug Events Dan Budnitz, MD, MPH National Center for Injury Prevention & Control November 9, 2004 Collaborative Effort.

Research Project #5 Develop Common Data on Accident Circumstances.

11 Mayview Regional Service Area Plan (MRSAP) Tracking: Supporting Individuals in the Community June 18, 2008.

SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes.

Good Pharmacovigilance Practices

Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.

CHART ROUND As an educational program?. …Chart Round Chart: to follow or record sth carefully and in detail. Round: a regular series of visits.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,

Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

THE NATIONAL VACCINE PROGRAM OFFICE NATIONAL ADULT IMMUNIZATION PLAN OVERVIEW.

12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.

Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.

Risk Assessment Meeting Introduction Slides --- Your Hospital’s Name --- Hospital at Night Patient Safety Risk Assessment:

Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.

FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

Risk Assessment Meeting Introduction Slides --- Your Hospital’s Name --- Hospital at Night Patient Safety Risk Assessment:

Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.

Documentation of pharmaceutical care

Risk Assessment Meeting

CHAPTER 4 Information Management in Pharmacy.

HOW TO FULFILL STATUTORY REQUIREMENTS ON PRODUCT RELATED HEALTH INFORMATION Samina Qureshi, M.D. PSI INTERNATIONAL Inc.

Overview of FDA Food Inspections

The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Patient Involvement in the Development and Safe Use of

FDA Sentinel Initiative

Model Enhanced Classification of Serious Adverse Events

Compounded Drugs and Lack of Premarket FDA-Approval

Module 6: Case Report Form (Chart Abstraction)

A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.

Presentation transcript:

Life Sciences Research Office (LSRO) Evaluating Adverse Event Reporting Systems for Dietary Supplements January 30-31, 2003 “Open Portion of Meeting”

Goals for AERS meeting January 30-31, 2003  Introduce importance, controversial nature and complexity of project  Present LSRO’s objectives  Begin to formulate plan to achieve objectives

Phase I Review and qualitatively compare AER in Metabolife and FDA databases Determine the usefulness of these AER as signals for product safety

Phase II Review systems for reporting adverse events for dietary supplements In a detailed LSRO report, recommend features of an AERS to the dietary supplement industry --How to collect, document, and respond to AER --How to evaluate aggregate data to obtain useful and reliable signals of potential problems

Critical issues that may be considered: AER systems for OTC drugs, foods and dietary supplements Models for evaluation of data Type of data necessary Additional data Responsibilities of consumers and healthcare providers Signals generated by evaluations of AER Types of responses associated with these signals

FDA CFSAN database of AER associated with dietary supplements containing ephedrine alkaloids Docket Number 00N-1200

FDA CFSAN AER associated with dietary supplements – Each AER is assigned a 5 digit case number – Each case has a chart – The chart has up to 9 sections

FDA CFSAN AER Chart Sections 1.Section 0 Incoming Report 2.Section 1 Affidavits 3.Section 2 Label Sample 4.Section 3 Outpatient Medical Reports 5.Section 4 ER/Urgent Care Records 6.Section 5 Hospital Record Summaries 7.Section 6 Hospital Medical Notes 8.Section 7 Hospital Surgical Reports 9.Section 8 Other (e.g., Autopsy Report)

FDA CFSAN AER Ephedrine Alkaloid-Containing Dietary Supplements (1990 through )  Total 1176 minus duplicates = 1164  Distribution by year (n=1126)  Ranked by frequency of product reported (n=499)

Pre-Case Seriesn=14 Prior to (and not in docket 95N-0304) New Case Seriesn= to Post Case Seriesn= to FDA CFSAN AER Ephedrine Alkaloid-Containing Dietary Supplements (Docket 00N-1200 obtained for LSRO review, n=273)

New Case Series (n=140)  Attributablen=22 [e.g., used as directed, temporal, de/rechallenge, signs and symptoms consistent with known effects of ephedrine]  Supportiven=38 [e.g., incomplete medical record, other confounding factors]  Insufficient Datan=72  Not Evaluatedn=8